This site is intended only for healthcare professionals residing in Singapore




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsMaterialsVideosLet’s connectLet's ConnectContact usPfizer medical information



Breast Cancer 

At Pfizer, we want to transform the landscape of cancer treatment and significantly improve the lives of cancer patients worldwide. We strive to bring innovative treatments to the forefront by developing therapies that provide maximum efficacy while minimizing adverse effects for the patient.

Pfizer Oncology supports people living with breast cancer by developing innovative medicines, providing educational resources, and helping to remove barriers to equitable care.

CDK4/6 Inhibitors in mBC

Embark on a journey to learn more about the management of HR+/HER2- metastatic breast cancer (mBC) through a wide range of resources including clinical data and real-world evidence.

Learn more

ELEVATE aims to provide an educational and interactive forum for medical oncologists and other physicians from across the globe. Pfizer supports medical education regarding latest evidence in the management of HR+/HER2- metastatic breast cancer, enabling translation of evidence into best practice for patient care.

Learn more
Abbreviations:CDK = cyclin-dependent kinase; HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; mBC = metastatic breast cancer
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.

Copyright © 2024 Pfizer Limited. All rights reserved.